Tracking Progress
Kitzerow's Theory Validation Progress Dashboard
Tracking progress across autism traits, comorbid traits, treatment development, and public awareness.
Kitzerow’s Autism and the Comorbidities Theoretical Model proposes that genetic and epigenetic factors activate an allostatic response that reallocates biological resources toward survival over typical development and function through the BH4 Shunt. This page tracks where evidence, treatment development, and research gaps currently stand.
The model is organized into a biological cascade composed of individual nodes. Each node represents a biologically delineated mechanism that has been implicated in autism, comorbid conditions, or comorbidity clustering.
The model does not propose the existence of these biological mechanisms. Rather, it proposes that they produce the specific autism traits, comorbid traits, and clustering patterns delineated within the cascade. If so, interventions that successfully target these mechanisms should modify or resolve the traits they produce.
This dashboard tracks the evidence supporting those proposed mechanism-trait relationships, along with treatment development and remaining research gaps.
Not: “Do these mechanisms exist”
But: “Do these mechanisms explain the traits and patterns predicted by the model, and is treatment at each node successful for each phenotype?”
Current Progress
2023 → 2026Raising Awareness
Next Steps
Continued awareness efforts are intended to encourage investigation of the model, promote interdisciplinary discussion, and facilitate collaboration across education, autism, neuroscience, allostasis, genetics, metabolism, and comorbidity research.
Available Beginning Fall 2026
- Conferences
- Podcasts
- Professional Development
- Educational Presentations
- Autism and Comorbidity Research Talks
For presentation, podcast, conference, or professional development requests, contact: kitzerow@kimberlyedu.org
Research Maturity Scale
How to Read the Progress Dots
🔴 Stage 1 — Theoretical
- Proposed mechanism
- Limited direct evidence
🟠 Stage 2 — Emerging Evidence
- Initial studies converge
- Mechanism becoming visible
🟡 Stage 3 — Converging Evidence
- Multiple independent groups reporting related findings
- Strong biological support
🟢 Stage 4 — Treatment or Diagnostic Development
- Mechanism being actively targeted
🔵 Stage 5 — Established
- Widely accepted mechanism with established interventions
NeuroToggle® Education
NeuroToggle® Education
NeuroToggle® is the educational application of the model. It applies neuroplasticity-based instruction to skills and behaviors by treating them as neural circuit outcomes.
NeuroToggle® Educational Framework
Mechanism
NeuroToggle® targets skill and behavior development through structured teaching that supports neural circuit formation, strengthening, expansion, and timing.
Converging Evidence
- Neurobiology of learning supports experience-dependent circuit change.
- Memory formation research supports repeated activation and refinement of pathways.
- Neuroplasticity research supports targeted experience as a driver of skill development.
Current Progress
- NeuroToggle® framework developed
- Books published
- Educator resources available
- Educator toolkit available
Research Gap
- NeuroToggle® is new.
- Implementation data is still accumulating.
- Long-term outcome evidence remains under development.
BioToggle®
Kitzerow's Autism and the Comorbidities Cascade
From Theory to Converging Evidence, Diagnostic, and Treatment Protocols
Developed in 2023 through the Jigsaw Puzzle Methodology, Kitzerow's Autism and the Comorbidities Cascade was created to organize biological findings across autism into a single explanatory framework. Many nodes within the cascade were initially theoretical or supported only by emerging evidence. Since then, converging evidence, diagnostic developments, and treatment pathways have continued to emerge across multiple nodes. The development of the model can be viewed on the Documented Discovery Timeline.
Similar to how plate tectonics organized previously disconnected observations about earthquakes, volcanoes, mountain ranges, and continental movement into a single explanatory framework, Kitzerow’s Autism and the Comorbidities Cascade organizes previously disconnected biomarkers, proteins, pathways, and clinical findings into a unified theoretical model of autism and systemic comorbidities.
Plate Tectonics
Before Plate Tectonics
- Earthquakes
- Volcanoes
- Mountain ranges
- Continental movement
Plate Tectonics
A theoretical model that explained how these observations were connected through movement of Earth's crust.
Kitzerow's Autism Cascade
Before the Cascade
- Biomarkers
- Protein pathways
- Genetic findings
- Clinical comorbidity patterns
Kitzerow's Autism Cascade
A theoretical model that organizes these findings into a unified explanation for autism traits, comorbid traits, comorbidity clustering, and chronic progressive conditions.
Autism Traits Cascade
Excitotoxic synaptic damage impacts memories for how to produce skills and behaviors.
Chronic Allostasis
Mechanism
Within the model, genetic and epigenetic factors chronically activate the regulatory system domains (Immune System, Metabolism, Cellular Repair, Nervous System, and Genetic Regulation) and disrupt the temporal system domains (Ultradian, Circadian, Circannual, Developmental, and Aging). The model proposes that this sustained allostatic state reallocates biological resources toward resolving the stress response and away from typical development and function, producing biochemically predictable downstream changes throughout the cascade. Persistent activation is further proposed to result in allostatic overload, contributing to the accumulation of compounding comorbid traits across regulatory domains.
Converging Evidence
- UCSD Dr. Naviaux’s 3-Hit Metabolic Signaling Model (2025) — Proposes that autism emerges through the interaction of genetic, chronic, and situational stressors...
- Santamaría-García et al. (2025) — Allostatic Interoception and Neurodevelopment.
- Makris et al. (2022) — Autonomic Nervous System Dysregulation in Autism.
- Increasing recognition of chronic physiological stress across autism research accompanied by genetic and epigenetic factors.
Current Treatment Approaches
- Biomedical approaches commonly target inflammation, oxidative stress, mitochondrial dysfunction, immune dysregulation, metabolic dysfunction, and other contributors to chronic physiological stress.
Research Gap
- Current approaches typically target individual pathways rather than regulatory-system domains and their interactions.
- The model predicts that restoring balance within and between regulatory domains may be more important than continuously driving individual pathways higher or lower.
- Better understanding is needed regarding biological set-point restoration across interconnected systems.
BH4 Shunt
Mechanism
Within the model, chronic allostasis activates the BH4 Shunt, a proposed redox-sensitive shift in GCH1 regulation that reallocates BH4-dependent biological resources toward survival functions as a core component of the stress response system. The model proposes that this redistribution initiates predictable downstream changes in BH4-dependent pathways involved in autism traits and comorbid traits. As a central regulator of multiple interconnected biological systems, BH4 Shunt activation is proposed to generate cascading effects that produce autism traits, comorbid traits, and comorbidity clustering.
Converging Evidence
- Filho et al. (2025): BH4 Systematic Review — Concluded that redox-regulated BH4 dysfunction impacts multiple interconnected biological systems that contribute to autism and associated comorbid traits.
Current Treatment Approaches
- Frye (2010): BH4 Treatment in Autism — Investigated tetrahydrobiopterin (BH4) as a therapeutic intervention for autism based on its role as a critical cofactor in neurotransmitter synthesis and nitric oxide metabolism. Sixty-three percent of participants demonstrated clinical improvement following BH4 treatment. The study approached BH4 dysfunction as a deficiency state rather than a BH4 shunt mechanism. Within Kitzerow’s model, variability in treatment response may reflect underlying BH4 pathway redistribution rather than BH4 deficiency alone.
- Klaiman et al. (2013): BH4 Placebo-Controlled Trial in Autism — Found significant improvements in social awareness, autism mannerisms, hyperactivity, and inappropriate speech following BH4 treatment compared to placebo.
Research Gap
- Existing interventions increase BH4 availability but do not directly target the proposed BH4 Shunt mechanism.
- The model predicts that increasing BH4 levels and modifying BH4 Shunt activation may not represent the same intervention target.
- Direct BH4 Shunt interventions have not yet been developed.
AGMO Shunt
Mechanism
Within the model, the AGMO Shunt is a BH4-dependent lipid-regulation mechanism that activates following a regulatory system set-point breach. AGMO regulates the catabolism of alkylglycerol ether lipids. Ether lipids include plasmanyl phospholipids, plasmalogens, platelet-activating factor (PAF), and endocannabinoid-related lipids such as noladin ether. The model proposes that changes in AGMO pathway activity alter lipid signaling and regulatory function across biological systems, producing comorbid traits. The specific traits produced by AGMO pathway dysregulation appear to be involved in social interaction and social avoidance.
Converging Evidence
- Dorninger et al. (2019): Ether Lipid Deficiency and Neurotransmitter Homeostasis — Using a Gnpat knockout mouse model of ether lipid deficiency, the authors demonstrated reduced neurotransmitter levels, altered neurotransmitter turnover, impaired vesicular monoamine transport, reduced neurotransmitter release, hyperactivity, and impaired social interaction.
- Smith et al. (2023): Ether Lipid and Glycerophospholipid Dysregulation in Autism — Identified reproducible alterations in ether lipid subclasses, glycerophospholipid domains, and long-chain polyunsaturated fatty acids including linoleic acid, arachidonic acid, and DHA in autistic individuals. This provides converging evidence that lipid pathways involved in membrane composition, ether lipid metabolism, and endocannabinoid precursor availability are altered in autism.
- Li et al. (2025): Lipidomic Reorganization in Autism — Found widespread alterations across interconnected lipid pathways, including ether lipids, glycerophospholipids, and arachidonic acid-containing lipid species. The pattern is more consistent with redistribution of lipid metabolism than isolated lipid deficiency. Within Kitzerow’s Autism and the Comorbidities Theoretical Model, these findings are consistent with an AGMO shunt in which lipid substrates are redirected across competing pathways, producing downstream effects on endocannabinoid signaling and lipid reallocation.
Current Treatment Approaches
- Folkes et al. (2020): Endocannabinoid Regulation of Excitatory-Inhibitory Neurotransmission — Demonstrated that increased glutamatergic activity within the basolateral amygdala–nucleus accumbens (BLA-NAc) circuit reduced social interaction and increased social avoidance. The authors further showed that 2-arachidonoylglycerol (2-AG) endocannabinoid signaling suppresses BLA-NAc glutamatergic activity, and that pharmacological augmentation of 2-AG normalized social interaction deficits in Shank3B−/− autism-model mice. Restoration of social behavior was accompanied by correction of abnormal excitatory and inhibitory neurotransmission and reduced feed-forward inhibition within the nucleus accumbens.
Research Gap
- Development of AGMO-targeted interventions.
AAAH Shunt
Mechanism
Within the model, activation of the BH4 Shunt produces the AAAH Shunt, a proposed redistribution of biochemical resources across transamination pathways and BH4-dependent neurotransmitter synthesis. The model proposes that glutamate is reallocated through transamination pathway activity while downstream dopamine and serotonin synthesis is altered according to physiological demands. Because this mechanism functions as a shunt rather than a deficiency state, neurotransmitter availability may increase or decrease depending on the type of stress, the biological resources required, and the needs of the stress response.
Converging Evidence
- Zhang et al. (2024): Branched-Chain Amino Acids and Autism — Found significantly elevated concentrations of branched-chain amino acids (BCAAs), including valine and leucine/isoleucine, in autistic children. The authors note that BCAAs compete with aromatic amino acids for transport across the blood-brain barrier, potentially reducing the availability of neurotransmitter precursors required for dopamine and serotonin synthesis. This provides converging evidence of an AAAH Shunt in autism biomarkers.
- Monoamine research in autism.
- Dopamine, serotonin, and catecholamine literature.
Current Treatment Approaches
- Downstream neurotransmitter systems are routinely targeted through existing medical interventions.
Research Gap
- No interventions currently target the proposed AAAH Shunt mechanism directly.
- Direct AAAH pathway investigation is still needed.
E/I Balance in CSTL Circuitry
Mechanism
Within the model, stress-dependent reallocation of glutamate through transamination pathway activity, together with altered dopamine and serotonin synthesis, changes the biological resources available for neural circuit regulation. The model proposes that these shifts alter the balance between excitation and inhibition within corticothalamostriatal loop (CSTL) circuitry, disrupting how information is processed, filtered, and integrated across neural networks. Because excitation and inhibition function as a dynamic regulatory system, imbalance may emerge through multiple patterns of neurotransmitter reallocation. The model proposes that disruption of E/I balance within CSTL circuitry directly produces core autism traits through predictable changes in movement, habit formation, reward processing, and other region-specific neural functions depending on which CSTL circuits are most affected. Excitotoxicity due to elevated glutamate levels may also produce regressive symptoms due to damage to synapses that hold the information for how to produce skills and behaviors.
Converging Evidence
- Sohal & Rubenstein (2019): Excitatory-Inhibitory Imbalance — Propose that altered excitatory-inhibitory (E/I) balance can reduce neural signal-to-noise ratios and contribute to autism. The authors further note that numerous developmental and genetic mechanisms may converge on E/I dysregulation. This provides converging evidence for the importance of E/I imbalance in autism. The primary difference is that Sohal and Rubenstein do not propose a converging biochemical cascade driving this imbalance, whereas Kitzerow’s Autism and the Comorbidities Theoretical Model proposes that genetic and epigenetic factors can contribute to BH4 pathway shunting, resulting in downstream neurotransmitter alterations and E/I dysregulation.
- Rubenstein & Merzenich (2003): Excitatory-Inhibitory Imbalance Hypothesis — Proposed that altered excitatory-inhibitory (E/I) balance, potentially driven by GABAergic interneuron dysfunction, contributes to autism by reducing neural signal-to-noise ratios and impairing information processing. This provides converging evidence for E/I dysregulation in autism. The primary difference is the proposed driver of the imbalance, with Kitzerow’s model implicating BH4 pathway shunting and downstream neurotransmitter alterations as an upstream mechanism.
- Bruining et al. (2020): EEG Evidence of Excitatory-Inhibitory Imbalance in Autism — Found that autistic children exhibited greater variability in functional excitatory-inhibitory (fE/I) balance and stronger long-range temporal correlations (LRTC) compared to typically developing controls. Notably, elevated fE/I and LRTC measures were observed even in autistic children with visually normal EEGs, suggesting that E/I dysregulation may be present despite the absence of conventional EEG abnormalities.
- Yale study by Naples et al. (2026): mGlu5 Availability and Excitatory Neurotransmission in Autism — Found approximately 15% lower mGlu5 receptor availability across multiple brain regions in autistic individuals, with the largest differences observed in the cerebral cortex. Lower mGlu5 availability was significantly associated with EEG measures of altered excitatory neurotransmission, suggesting that reduced mGlu5 signaling may contribute to excitation-inhibition dysregulation in autism. This provides converging evidence that altered excitatory neurotransmission is a measurable biological feature of autism.
- Essa et al. (2012): Excitotoxicity and Neuronal Injury — Reviewed evidence that excessive glutamatergic activity can produce excitotoxicity, oxidative stress, mitochondrial dysfunction, and neuronal damage in autism. This provides converging evidence that neurotransmitter dysregulation can injure established neural circuits. Within Kitzerow’s Autism and the Comorbidities Theoretical Model, because neural circuits and their synaptic connections store the information required to produce skills and behaviors, excitotoxic damage to these circuits provides a potential mechanism for regression and loss of previously acquired abilities.
- Ansary & Al-Ayadhi (2014): Glutamate Excitotoxicity and Synaptic Dysregulation — Reported elevated glutamate levels, evidence of excitotoxicity, altered GABAergic signaling, and associations with neuroinflammatory markers in autistic individuals. This provides converging evidence for excitatory-inhibitory imbalance in autism. The primary distinction is that the authors attribute the imbalance primarily to neuroinflammatory processes, whereas Kitzerow’s model proposes BH4 pathway shunting as an upstream driver of neurotransmitter dysregulation and excitotoxic stress.
- Nature Neuroscience connectivity subtype findings.
- Kern et al. (2013): Neurodegeneration and Regression in Autism — Proposed that regression in autism may reflect neurodegenerative or progressive encephalopathic processes and highlighted evidence of age-related neurological deterioration in some autistic individuals. This provides converging evidence that loss of previously acquired skills may involve damage to established neural systems. Within Kitzerow’s model, regression is proposed to occur when biological stressors disrupt neural circuits and synapses that store learned skills and behaviors.
Current Treatment Approaches
- Jang et al. (2025): Reticular Thalamic Hyperexcitability and Autism Behaviors — Found that hyperexcitability of the reticular thalamic nucleus (RT) contributed to autism-related behaviors in a Cntnap2 mouse model. Pharmacological suppression using the T-type calcium channel blocker Z944 and chemogenetic inhibition of RT activity significantly improved social deficits, repetitive behaviors, hyperactivity, and seizure-related phenotypes.
- Roh et al. (2026): NMDAR Hypofunction Rescue in SHANK2 and SHANK3 Models — Found that inhibition of the glycine transporter SLC6A20 restored NMDA receptor (NMDAR) function, rescued abnormal synaptic phospho-proteomic signaling, and normalized ASD-related behavioral phenotypes in SHANK2- and SHANK3-mutant mice. Similar restoration of NMDAR function was observed in human cortical organoids carrying SHANK2 or SHANK3 mutations.
Research Gap
- Existing interventions target downstream circuitry.
- Upstream mechanisms driving E/I imbalance remain largely unaddressed.
Synaptic Pruning / mTOR Regulation
Mechanism
Within the model, synaptic pruning patterns are altered by changes in mTOR activity resulting from chronic allostasis and redox-sensitive protein regulation. Because synaptic pruning determines which neural connections are retained and which are eliminated, altered pruning patterns change the organization of neural circuitry throughout development. The model proposes that this produces predictable connectivity differences, including hyperconnectivity, hypoconnectivity, altered network specialization, and altered neural circuit maturation. While epigenetic redox-sensitive protein shunts are described within the comorbid trait mechanisms, their impact on neural circuitry places this node within the autism trait mechanisms.
Converging Evidence
- Ojha et al. (2026): Nitric Oxide-Mediated mTOR Dysregulation — Demonstrated that nitric oxide-mediated S-nitrosylation of TSC2 drives mTOR overactivation in both Shank3 and Cntnap2 autism models. This provides converging evidence that dysregulated nitric oxide signaling can function as an upstream regulator of mTOR activity, a pathway known to influence protein translation, synaptic development, and synaptic pruning.
- Pagani et al. (2021): mTOR-Dependent Synaptic Pruning and Autism — Reported that postmortem studies consistently demonstrate increased density of excitatory synapses in autistic brains, a finding linked to impaired mTOR-dependent synaptic pruning. Using a Tsc2 mouse model, the authors showed that mTOR-driven increases in dendritic spine density were associated with ASD-like behaviors and functional hyperconnectivity, both of which were rescued by mTOR inhibition.
Current Treatment Approaches
- Mechanistic convergence is emerging.
Research Gap
- No treatment pathway currently targets this mechanism directly.
- Translation of mechanistic findings into interventions remains needed.
Comorbid Traits Cascade
Chronic Allostasis
Mechanism
Within the model, genetic and epigenetic factors chronically activate the regulatory system domains (Immune System, Metabolism, Cellular Repair, Nervous System, and Genetic Regulation) and disrupt the temporal system domains (Ultradian, Circadian, Circannual, Developmental, and Aging).
The model proposes that this sustained allostatic state reallocates biological resources toward resolving the stress response and away from typical development and function, producing biochemically predictable downstream changes throughout the cascade.
Persistent activation is further proposed to result in allostatic overload, contributing to the accumulation of compounding comorbid traits across regulatory domains.
Converging Evidence
- UCSD Dr. Naviaux’s 3-Hit Metabolic Signaling Model (2025) — Proposes that autism emerges through the interaction of genetic, chronic, and situational stressors, resulting in persistent metabolic and mitochondrial alterations that affect neurodevelopment. The model follows a similar cascade of genetic/chronic/situational factors → metabolic shift → E/I dysregulation → autism and comorbidities → developmental timing → neuroplasticity.
- Santamaría-García et al. (2025) — Allostatic Interoception and Neurodevelopment. Propose that allostatic-interoceptive processes are crucial during critical periods of neurodevelopment and that their disruption is linked to autism.
- Makris et al. (2022) — Reviewed evidence showing that autistic children and adolescents consistently demonstrate lower parasympathetic nervous system (PNS) activity alongside higher sympathetic nervous system (SNS) activity at rest.
- Increasing recognition of chronic physiological stress across autism research accompanied by genetic and epigenetic factors.
Current Treatment Approaches
- Biomedical approaches commonly target inflammation, oxidative stress, mitochondrial dysfunction, immune dysregulation, metabolic dysfunction, and other contributors to chronic physiological stress.
Research Gap
- Current approaches typically target individual pathways rather than regulatory-system domains and their interactions.
- The model predicts that restoring balance within and between regulatory domains may be more important than continuously driving individual pathways higher or lower.
- Better understanding is needed regarding biological set-point restoration across interconnected systems.
BH4 Shunt
Mechanism
Within the model, chronic allostasis activates the BH4 Shunt, a proposed redox-sensitive shift in GCH1 regulation that reallocates BH4-dependent biological resources toward survival functions as a core component of the stress response system.
The model proposes that this redistribution initiates predictable downstream changes in BH4-dependent pathways involved in autism traits and comorbid traits.
As a central regulator of multiple interconnected biological systems, BH4 Shunt activation is proposed to generate cascading effects that produce autism traits, comorbid traits, and comorbidity clustering.
Converging Evidence
- Filho et al. (2025): BH4 Systematic Review — Concluded that redox-regulated BH4 dysfunction impacts multiple interconnected biological systems that contribute to autism and associated comorbid traits.
Current Treatment Approaches
- Frye (2010): BH4 Treatment in Autism — Investigated tetrahydrobiopterin (BH4) as a therapeutic intervention for autism based on its role as a critical cofactor in neurotransmitter synthesis and nitric oxide metabolism. Sixty-three percent of participants demonstrated clinical improvement following BH4 treatment. Within Kitzerow’s model, variability in treatment response may reflect underlying BH4 pathway redistribution rather than BH4 deficiency alone.
- Klaiman et al. (2013): BH4 Placebo-Controlled Trial in Autism — Found significant improvements in social awareness, autism mannerisms, hyperactivity, and inappropriate speech following BH4 treatment compared to placebo.
Research Gap
- Existing interventions increase BH4 availability but do not directly target the proposed BH4 Shunt mechanism.
- The model predicts that increasing BH4 levels and modifying BH4 Shunt activation may not represent the same intervention target.
- Direct BH4 Shunt interventions have not yet been developed.
NOS Shunt
Mechanism
Within the model, the NOS Shunt is a BH4-dependent mechanism that activates following a regulatory system set-point breach.
When coupled, nitric oxide synthase produces nitric oxide. When uncoupled, it produces reactive oxygen species (ROS). Nitric oxide and ROS can also combine to form peroxynitrite.
The model proposes that nitric oxide, ROS, and peroxynitrite function as signaling molecules that coordinate the regulatory system response across the Immune System, Metabolism, Cellular Repair, Nervous System, and Genetic Regulation domains.
Converging Evidence
- Khan & Dewald (2024): Nitric Oxide and Peroxynitrite as Autism Biomarkers — Proposed nitric oxide and peroxynitrite as potential biomarkers for autism based on findings from induced pluripotent stem cells and brain organoids derived from autistic individuals. The study suggests that dysregulated nitric oxide signaling may be sufficiently robust to serve as a measurable biological feature of autism.
- Fu et al. (2019): Altered Nitric Oxide Metabolism in Autism — Reported significantly elevated urinary nitrite, reduced urinary nitrate, and increased nitrite-to-nitrate ratios in autistic children. Rather than indicating a simple increase or decrease in nitric oxide activity, the altered distribution of nitric oxide metabolites suggests disruption of nitric oxide pathway regulation. This provides converging evidence that NOS-related metabolism is altered in autism. Within Kitzerow’s Autism and the Comorbidities Theoretical Model, such findings are consistent with NOS pathway shunting and altered downstream nitric oxide signaling.
- Khan & Dewald (2026): Nitric Oxide as a Differential Diagnostic Biomarker — Using carbon fiber-based porphyrinic nanosensors and autism-derived induced pluripotent stem cells, the authors found dramatically reduced nitric oxide production in autism (~6 nM) compared to healthy controls (~65 nM), with levels also distinguishable from intellectual disability (~11 nM). The authors proposed real-time nitric oxide measurement as a potential biomarker for both diagnosis and differential diagnosis of autism.
Current Treatment Approaches
- Research is increasingly identifying downstream effects of nitric oxide dysregulation.
Research Gap
- No interventions currently target the proposed NOS Shunt directly.
- Direct NOS Shunt interventions remain needed.
Epigenetic Redox-Sensitive Protein Shunts
Mechanism
Within the model, epigenetic redox-sensitive protein shunts function as regulatory system effectors that activate in response to ROS signaling following a regulatory system set-point breach.
The model proposes that these effectors alter pathway activity within the Immune System, Metabolism, Cellular Repair, Nervous System, and Genetic Regulation domains to support adaptation to ongoing physiological demands.
These alterations in pathway activity are proposed to produce comorbid traits.
Converging Evidence
mTOR Shunt
- Pagani et al. (2021): mTOR-Dependent Synaptic Pruning and Autism — Reported that postmortem studies consistently demonstrate increased density of excitatory synapses in autistic brains, a finding linked to impaired mTOR-dependent synaptic pruning. Using a Tsc2 mouse model, the authors showed that mTOR-driven increases in dendritic spine density were associated with ASD-like behaviors and functional hyperconnectivity, both of which were rescued by mTOR inhibition.
- Ojha et al. (2026): Nitric Oxide-Mediated mTOR Dysregulation — Demonstrated that nitric oxide-mediated S-nitrosylation of TSC2 drives mTOR overactivation in both Shank3 and Cntnap2 autism models. This provides converging evidence that dysregulated nitric oxide signaling can function as an upstream regulator of mTOR activity.
Immune Regulatory Shunts
- Complement pathway findings
- Immune signaling findings
- hEDS immune pathway findings
Cellular Repair Shunts
- Extracellular matrix remodeling
- Connective tissue regulation
- hEDS findings
Metabolic Regulatory Shunts
- Oxidative stress signaling
- Mitochondrial adaptation
- Metabolic pathway regulation
Current Treatment Approaches
- No targeted interventions currently identified.
Research Gap
- Additional epigenetic redox-sensitive protein shunts likely remain unidentified.
- Mechanism-specific interventions have not yet been developed.
Allostatic Overload
Mechanism
Within the model, allostatic overload occurs when regulatory system set points fail to restore to baseline and allostatic mechanisms remain active for prolonged periods of time.
The model proposes that prolonged activation of these allostatic mechanisms creates cumulative biological wear across the Immune System, Metabolism, Cellular Repair, Nervous System, and Genetic Regulation domains.
As biological resources continue to be prioritized toward adaptation and stress resolution, maintenance and repair functions become increasingly compromised. The model proposes that this biological burden contributes to the development of chronic progressive comorbid conditions.
Converging Evidence
- Neurodegenerative and neuromuscular autism comorbidities.
- Nadeem et al. (2021): Overlapping Neurodevelopmental and Neurodegenerative Pathways — Identified shared molecular mechanisms between autism and Alzheimer’s disease involving APP processing, protein regulation, and cellular signaling networks. This provides converging evidence that pathways implicated in autism can overlap with mechanisms associated with long-term neurodegeneration. Within Kitzerow’s Autism and the Comorbidities Theoretical Model, such overlap is consistent with the hypothesis that prolonged dysregulation across interconnected biological systems may contribute to cumulative physiological burden and the development of chronic progressive comorbid conditions.
- Phillips et al. (2026): Shared Cerebrospinal Fluid Clearance Abnormalities in Autism and Alzheimer’s Disease — Proposed that impaired cerebrospinal fluid (CSF) drainage through lymphatic, glymphatic, perivascular, and nasal clearance pathways may contribute to both autism and Alzheimer’s disease. The authors highlight evidence that individuals with ASD and AD exhibit increased extra-axial CSF, enlarged perivascular spaces, glymphatic dysfunction, olfactory abnormalities, and altered processing of tau and amyloid proteins. This provides converging evidence that autism and neurodegenerative disorders may share mechanisms involving impaired biological waste clearance and accumulation of cellular burden. Within Kitzerow’s Autism and the Comorbidities Theoretical Model, these findings are consistent with the concept that prolonged dysregulation across interconnected regulatory systems can produce cumulative physiological burden over time.
Current Treatment Approaches
- Primarily symptom management.
- Domain-specific interventions.
Research Gap
- Better understanding of how overload progresses across interconnected regulatory domains.
Comorbidity Clustering
Mechanism
Within the model, comorbidity clustering emerges from the interconnected nature of BH4-dependent pathways and the regulatory system domains.
The model proposes that activation of the BH4 Shunt produces coordinated changes across the Immune System, Metabolism, Cellular Repair, Nervous System, and Genetic Regulation domains because these systems do not function independently.
As pathway activity shifts within one domain, downstream effects can propagate throughout the broader regulatory network.
The model proposes that this biological interconnectedness results in predictable patterns of co-occurring traits and conditions rather than isolated comorbidities.
Converging Evidence
- Litman et al. (2025) — Princeton researchers demonstrated that phenotypic and clinical outcomes correspond to genetic and molecular programs of common, de novo, and inherited variation and further characterized distinct biological pathways disrupted by each class of mutation. These findings provide converging evidence that autism traits and comorbid traits may emerge through coordinated biological programs rather than isolated genetic effects, consistent with the model's prediction of comorbidity clustering across interconnected regulatory domains.
- Autism-comorbidity clustering observations.
Current Treatment Approaches
- Symptom-specific treatment approaches.
Research Gap
- Predictive clustering models.
- Cluster-specific interventions.
- Earlier identification of regulatory patterns before multiple comorbid traits emerge.
Regulatory System Domains
Mechanism
Within the model, comorbid traits emerge when epigenetic redox-sensitive protein shunts alter pathway activity within specific regulatory system domains. These protein shunts function as regulatory system effectors that modify biological activity following a set-point breach.
Because each domain contains distinct pathways, proteins, and biological functions, activation of different protein shunts can produce different comorbid traits. The examples below highlight representative mechanisms that may contribute to trait development within each domain.
The model organizes these effects into five interconnected regulatory system domains: Immune System, Metabolism, Cellular Repair, Nervous System, and Genetic Regulation. While separated for clarity, these domains interact continuously and changes within one domain may propagate throughout the broader regulatory network.
Immune System Domain
KEAP1 Shunt
The KEAP1 Shunt regulates antioxidant defense activation through the KEAP1-NRF2 pathway.
ROS-mediated activation shifts biological resources toward glutathione synthesis, detoxification, redox buffering, and damage control.
The model proposes that prolonged activation alters immune signaling, inflammatory regulation, and metabolic allocation, producing immune-related comorbid traits.
Examples
- Antioxidant response
- Inflammatory signaling
- Immune tolerance alterations
Current Treatment Approaches
- No targeted interventions currently identified.
Major Gap
- Mechanism-specific interventions.
Metabolism Domain
MTR Shunt
The MTR Shunt regulates one-carbon metabolism and methylation capacity.
The model proposes that MTR activity reallocates methylfolate, cobalamin, homocysteine, and transsulfuration pathway resources according to metabolic demands.
These shifts alter methylation, glutathione production, energy metabolism, and redox regulation, producing metabolic comorbid traits.
Examples
- Methylation changes
- Glutathione regulation
- Homocysteine metabolism
- Energy production
Current Treatment Approaches
- Pathway-specific nutritional and metabolic interventions.
Major Gap
- Direct BH4 Shunt interventions.
Cellular Repair Domain
MMP Shunt
The MMP Shunt regulates extracellular matrix turnover and remodeling.
The model proposes that altered MMP activity shifts cellular resources between tissue maintenance, repair, and degradation.
Persistent dysregulation may impair connective tissue integrity and structural maintenance, producing cellular repair-related comorbid traits.
Examples
- hEDS
- Connective tissue dysfunction
- Extracellular matrix remodeling
- Chronic pain syndromes
Current Treatment Approaches
- Primarily symptom-based management approaches.
Major Gap
- MMP-targeted therapies.
Nervous System Domain
CRH Shunt
The CRH Shunt regulates neuroimmune stress signaling through activation of the hypothalamic-pituitary-adrenal (HPA) axis.
The model proposes that persistent CRH activation reallocates resources toward stress adaptation and alters immune, endocrine, and nervous system regulation, producing stress-related comorbid traits such as burnout.
Examples
- POTS
- Dysautonomia
- Sensory regulation
Converging Evidence
- Mahoney & O'Ryan (2022): Social Camouflaging and Allostatic Overload — Propose that chronic social camouflaging functions as an allostatic stressor that can contribute to allostatic overload and autistic burnout. While the proposed source of allostasis differs from Kitzerow’s model, the study provides converging evidence that prolonged allostatic burden may contribute to autistic burnout.
mTOR Shunt
The mTOR Shunt regulates the balance between anabolic growth programs and catabolic repair programs.
The model proposes that altered mTOR activity reallocates resources between protein synthesis, autophagy, mitochondrial function, and cellular repair.
Within the autism trait mechanisms, altered mTOR activity influences synaptic pruning and neural circuit maturation. Within the comorbid trait mechanisms, it alters broader cellular regulation.
Examples
- Synaptic pruning
- Protein synthesis
- Autophagy
- Cellular growth regulation
VEGFA Shunt
The VEGFA Shunt regulates neurovascular support, angiogenesis, and tissue oxygenation.
The model proposes that altered VEGFA activity changes sensory-neurovascular development and maintenance, producing nervous system comorbid traits.
Examples
- Sensory system development
- Hearing differences
- Vision differences
- Orofacial motor differences
- Neurovascular integrity
ACE Shunt
The ACE Shunt regulates vascular tone, neurovascular signaling, and kinetic filtering through the renin-angiotensin system.
The model proposes that altered ACE activity shifts resources toward circulatory pressure maintenance and inflammatory signaling, producing nervous system and autonomic comorbid traits.
Examples
- POTS
- Dysautonomia
- Neurovascular regulation
- Sensory regulation
Major Gap
- ACE2-targeted research.
Genetic Regulation Domain
p53 Shunt
The p53 Shunt regulates genomic preservation and damage control.
The model proposes that activation reallocates resources away from growth and specialization toward DNA repair, cell-cycle arrest, and cellular cleanup.
Chronic activation may reduce regenerative capacity and contribute to age-related or repair-related comorbid traits such as cancer.
Examples
- DNA repair
- Cellular senescence
- Apoptosis
- Genomic stability
Current Treatment Approaches
- Research remains focused on downstream pathway activity.
Major Gap
- Protein-shunt-targeted interventions.